Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03780816 · ClinicalTrials.gov registry record
Variation in Cancer Centers' End-of-Life Quality
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 473
- Enrollment target
NCT03780816: Completed study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03780816 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 473 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03780816 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 473 participants
- Enrollment target
Study Summary
This is a qualitative study of local organizational and provider practice norms, and how these norms influence patient and family expectations and provider decision-making heuristics for minority patients with advanced cancer at major US cancer centers. Outpatient visits with oncologists will be observed and documented via hand-written field notes. Semi-structured interviews with selected participating clinicians, patients, caregivers, and other informants will follow the initial observation.
Primary Outcome
Formal and informal norms influencing provider decision making (regarding receipt of chemotherapy in the last 14 days of life, intensive care unit (ICU) admission in the last 30 days of life, and non or late hospice referral) will be assessed using ethnographic observation in outpatient oncology clinics, multidisciplinary tumor boards, emergency departments, inpatient units, and other appropriate settings. All observations will be hand-written and later transcribed. Observations will be coded us
Interventions
- OTHER Observation of provider-patient interactions and interviews
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 473 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2021-07-15 |
What the finished NCT03780816 record still lists
NCT03780816 is an observational study that tracks outcomes without assigning an intervention. The registered 473 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observation of provider-patient interactions and interviews is the first listed.
NCT03780816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03780816 about?
NCT03780816 is a clinical study titled "Variation in Cancer Centers' End-of-Life Quality". This is a qualitative study of local organizational and provider practice norms, and how these norms influence patient and family expectations and provider decision-making heuristics for minority patients with advanced cancer at major US cancer centers. Outpatient visits with oncologists will be obs...
What is the current status of trial NCT03780816?
This trial is currently completed. The enrollment target is 473 participants. The study started on 2019-07-05. Estimated completion is 2021-07-15.
What interventions are being tested in trial NCT03780816?
The interventions under investigation include: Observation of provider-patient interactions and interviews (OTHER).
Who is sponsoring clinical trial NCT03780816?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI